Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported) December 14, 2004

                              Pharmion Corporation
             (Exact name of registrant as specified in its charter)

          Delaware                     000-50447                 84-1521333
          --------                     ---------                 ----------
(State or other jurisdiction       (Commission File             (IRS Employer
     of incorporation)                  Number)              Identification No.)

2525 28th Street, Boulder, Colorado                                      80301
-----------------------------------                                      -----
(Address of principal executive offices)                              (Zip Code)

Registrant's telephone number, including area code 720-564-9100

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

          On December 14, 2004, Erle T. Mast, our Chief Financial Officer,
          Judith A. Hemberger, our Chief Operating Officer and a member of our
          Board of Directors, and Gillian C. Ivers-Read, our Vice President
          Clinical Development and Regulatory Affairs, adopted pre-arranged
          stock trading plans in accordance with guidelines specified under Rule
          10b5-1 of the Securities Exchange Act of 1934 and our insider trading

          The plans allow for sales of up to 27,500 shares of our common stock
          held by Mr. Mast, 71,995 shares of our common stock held by Ms.
          Hemberger and 15,202 shares of our common stock held by Ms. Ivers-Read
          in a systematic manner during a period commencing in February 2005 and
          ending in December 2005 and subject to our common stock trading above
          certain pre-arranged minimum prices. A portion of the shares to be
          sold under these plans will be issued pursuant to the exercise of
          existing stock options held by the executives.

          Sales made pursuant to these plans will be disclosed publicly through
          Form 4 and Form 144 filings with the Securities and Exchange

          These plans will permit certain of our executive officers to sell a
          portion of their holdings in our common stock over time as part of
          their respective long-term strategies for asset diversification and
          tax planning.

          Rule 10b5-1 allows corporate officers to establish prearranged written
          plans to buy or sell a specified number of shares of company stock
          over a set period of time. A plan must be adopted in good faith at a
          time when the corporate officer does not possess material nonpublic
          information about the company. Once a plan is established, the
          executive does not retain any discretion over the subsequent sales of
          the shares.



     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                        PHARMION CORPORATION

Date: December 14, 2004                 By: /s/ Erle T. Mast
                                            Erle T. Mast
                                            Chief Financial Officer